Tom Monath joins TWiV to discuss his wide-ranging career that includes medicine, field work and vaccine development while working for the US government, the US military, and multiple biotechnology companies.
In his weekly clinical update Dr. Griffin reviews the public health response to poliovirus in New York, impact of mandatory influenza vaccination, monkeypox in a young infant, health care worker exposure to monkeypox virus, monkeypox testing delays, transmission potential of monkeypox virus, TPOXX trial for monkeypox, detection of SARS-CoV-2 subgenomic mRNA, mucosal IgA against SARS-CoV-2, BNT262b2 against Omicron, awareness and use of SARS-CoV-2 antivirals, comparable outcomes for Bebtelovimab and Nirmatrelvir, and COVID-19 and Alzheimer’s disease.
From the European Society for Clinical Virology 2022 Conference in Manchester UK, Vincent speaks with Emma Thomson about the recent outbreak of pediatric hepatitis of unknown etiology and the finding that it is linked to infection by adenovirus-associated virus 2.
In his weekly clinical update Dr. Griffin discusses detection of a highly divergent type 3 vaccine-derived poliovirus in a child with a severe primary immunodeficiency disorder, severe respiratory illnesses associated with rhinoviruses and/or enteroviruses including EV-D68, effects of vaccination and previous infection on Omicron infections in children, COVID-19-associated hospitalizations among vaccinated and unvaccinated adults 18 years or older in 13 US states, effectiveness of COVID-19 vaccines over time prior to Omicron emergence in Ontario, Canada, nasal IgA wanes 9 months after hospitalization with COVID-19 and is not induced by subsequent vaccination, resistance of SARS-CoV-2 Omicron subvariant BA.4.6 to antibody neutralization, persistent circulating SARS-CoV-2 spike associated with post-acute COVID-19 sequelae, and impact of COVID-19 vaccination on the risk of developing long-covid and on existing long-covid symptoms.
Vincent travels to Cornell University to speak with Cedric about his career and his research on mobile genetic elements such as transposons and endogenous viruses and how they have shaped the evolution of nearly all organisms.
In his weekly clinical update Dr. Griffin discusses variant influenza virus infections: recommendations for identification, treatment, and prevention for summer and fall 2022, low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals, using the right tools at the right time for SARS-COV-2 infection, onset and window of SARS-COV-2 infectiousness and temporal correlation with symptom onset, transmission of SARS-COV-2: a review of viral, host, and environmental factors, antibody persistence and safety through 6 months after heterologous orally aerosolized Ad5-nCoV in individuals primed with two-dose vaccine, timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients, administration of anti–SARS-COV-2 monoclonal antibodies after US Food and Drug Administration deauthorization, and clinical and genetic risk factors for acute incident venous thromboembolism in ambulatory patients with COVID-19.
TWiV discusses a new henipavirus from fruit bats in Madagascar, and attenuation of SARS-CoV-2 Omicron disease in mice caused by genome mutations outside of the spike protein coding region.
In his weekly clinical update Dr. Griffin discusses vaccine effectiveness against influenza illness in children, clinical manifestations of infection with poliovirus, spike protein-independent attenuation of SARS-CoV-2 Omicron variant in laboratory mice, concordance of SARS-CoV-2 results in self-collected nasal swabs vs swabs collected by health care workers in children and adolescents, probable animal-to-human transmission of SARS-CoV-2 causing a pet shop-related outbreak, laboratory-confirmed COVID-19–associated hospitalizations among adults during BA.2 variant, SARS-CoV-2 specific T-cells and antibodies, Nirmatrelvir use and outcomes during the Omicron surge, real-world effectiveness of early Molnupiravir or Nirmatrelvir–ritonavir in hospitalized patients, and distinguishing features of long COVID.
TWiV reviews the genetic characterization of a new strain of type 2 oral polio vaccine and its implications for eradication, and how a polymorphism in humans comprising a single amino acid change in an antibody molecule regulates vaccine elicitation of broadly neutralizing antibodies against influenza virus HA.
In his weekly clinical update Dr. Griffin discusses antibody response against nonpoliovirus enteroviruses, clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain, object and surface contamination with monkeypox virus, monkeypox virus infection in humans across 16 countries, clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection, compassionate use of Tecovirimat for the treatment of monkeypox infection, monitoring of Pfizer-BioNTech vaccine among children, Pfizer and BioNTech announce updated vaccine data supporting efficacy in children, direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer, Pfizer and BioNTech submit application for bivalent vaccine, and Oral Nirmatrelvir and Ritonavir in non-hospitalized vaccinated patients with COVID-19.